Welcome to Feed the Bull - A home for investment information and interaction.


Calgon Carbon and Cal Dive Awarded Multi-Million Dollar Contracts! DrStockPick Report On CCC, DVR, PWRM and CAI.

Posted, by drstockpick on October 6th, 2010

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of Power3, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."

"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.


CAI International, Inc. (NYSE:CAP), one of the world's leading lessors of intermodal freight containers, recently reported the following organizational changes:

* Victor Garcia is promoted to Senior Vice President and Chief Operating Officer and will no longer serve as the company's Chief Financial Officer.
* Gary Sawka is appointed Interim Chief Financial Officer until a permanent replacement for the Chief Financial Officer position is found. During his service as Interim Chief Financial Officer he no longer satisfies the New York Stock Exchange independence requirements for Directors and as a result resigned from the Board of Directors. It is intended that he will be nominated to the Board of Directors after concluding his employment as Interim Chief Financial Officer.
* David Remington is appointed to the Board of Directors as an independent Director and also assumes the role as the Chairman of the company's Nominating and Corporate Governance Committee.

CAI is one of the world's leading managers and lessors of intermodal freight containers. As of June 30, 2010, the company operated a worldwide fleet of approximately 776,000 TEUs of containers through 12 offices located in 10 countries including the United States.


Cal Dive International, Inc. (NYSE:DVR) has been awarded a contract for removal of a large jetty and installation of a new platform and eleven pipelines in Freeport, Bahamas. The contract is expected to generate total revenue of approximately $56 million and will utilize the Company's pipelay barge Lone Star, derrick barge Pacific, and one of its 4-Point dive support vessels. The Company had included approximately $38 million of this contract amount in its reported backlog as of June 30, 2010 based on a signed letter of intent at that time.

Cal Dive International, Inc., headquartered in Houston, Texas, is a marine contractor that provides an integrated offshore construction solution to its customers, including manned diving, pipelay and pipe burial, platform installation and platform salvage services to the offshore oil and natural gas industry on the Gulf of Mexico OCS, Northeastern U.S., Latin America, Southeast Asia, China, Australia, the Middle East, India and the Mediterranean, with a fleet of 29 vessels, including 19 surface and saturation diving support vessels and 10 construction barges.


Calgon Carbon Corporation's (NYSE: CCC) wholly owned subsidiary, Hyde Marine, Inc., has been awarded a contract by a leading South Korean shipyard to supply Hyde GUARDIAN Ballast Water Treatment (BWT) Systems for several tankers being built for a major Greek ship owner. The contract is valued at approximately $19.8-million USD.

Hyde GUARDIAN Systems will be delivered for 10 Suez-Max Crude Oil Tankers beginning in 2011 through 2013.

Hyde Marine, a recent addition to Calgon Carbon's UV Technologies Division, is a global market leader in the growing BWT market having sold more than 70 Type Approved systems to date. The Hyde GUARDIAN unit received International Maritime Organization (IMO) Type Approval in April 2009 and was the first BWT System accepted into the U.S. Coast Guard STEP program in October of 2008. The Hyde GUARDIAN system is chemical free, using filtration and ultraviolet disinfection to treat ships' ballast water to prevent the spread of invasive species from port to port.

Calgon Carbon Corporation, headquartered in Pittsburgh, Pennsylvania, is a global leader in services and solutions for making water and air safer and cleaner.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired.

Authored by, drstockpick
Log in or register to post Private Message
Advertise with us

Add new comment

By submitting this form, you accept the Mollom privacy policy.